The Influence of Fish Consumption on Polyunsaturated Fatty Acid (PUFA) Status (iFish)

December 4, 2018 updated by: University of Ulster

The Influence of Fish Consumption on Polyunsaturated Fatty Acid (PUFA) Status (iFish Study)

Polyunsaturated fatty acids (PUFA) are important for health, for example for the immune system, heart health and the brain. PUFA are found in fish, nuts and oils; including these foods in the diet provides the body with PUFA. The body can also produce some PUFA in a series of steps. It has been found that genetics influences the levels of PUFA produced in the body. This study will investigate whether fish consumption influences PUFA status in women of childbearing age when accounting for FADS genotype by conducting a controlled human intervention study. Participants will be asked to consume none, one or two portions of oily fish per week for 8 weeks and their response in PUFA status measured. This study will also use collected blood, hair, urine and faecal samples collected from the intervention study to explore other biomarkers of fish consumption. The aim of this study is to investigate whether fish consumption influences PUFA status in women of childbearing age when accounting for FADS genotype and to explore the potential of a novel biomarker, using hair MeHg:δ34S values, to accurately predict fish consumption. The study will initially involve providing a buccal swab sample which will investigate genes which are related to fatty acids. The participant will provide a buccal swab sample so that their genotype can be determined. The researcher who will contact the participant once genotype has been determined to arrange a baseline appointment. Participants will attend the Human Intervention Studies Unit at Ulster University, Coleraine once or twice weekly for a period of 8 weeks where they will receive lunch. This lunch will contain either tuna, sardines, or no fish depending on the intervention group you will be allocated to. Examples of lunch time meals they may receive include sandwiches, baked potato or salad which will include the type of fish they have been allocated to receive. Those allocated to the no fish group will receive a fish free alternative lunch. Participants will be asked to continue to follow their normal diet and lifestyle over the intervention period of 8 weeks. All participants will attend a baseline and post intervention appointment where they will have weight, height and body composition measured. Participants will also complete questionnaires to provide medical, lifestyle and dietary information. All participants will be asked to provide a sample of blood, urine, hair and faeces to assess biomarkers of fish consumption at baseline and post intervention appointments. Collected blood, urine, hair and faecal samples will be analysed for biomarkers of fish consumption. Participants will also be asked to return to the Human Intervention Studies Unit (HISU) 8 weeks after the intervention study has been completed (week 16) to provide a third hair sample and complete a Fish Feedback Questionnaire. In the 8 wks following conclusion of the study they will be free to return to their normal diet.

Study Overview

Study Type

Interventional

Enrollment (Actual)

49

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Co.Londonderry
      • Coleraine, Co.Londonderry, United Kingdom, BT52 1SA
        • Human Intervention Studies Unit, Ulster University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 41 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy females - premenopausal, child-bearing age, not planning to become pregnant
  • Age 18-45years old
  • Low consumers of fish (<2 portions/ week) or those willing to reduce their fish consumption one month prior to commencing the study to the equivalent of 2 portions per month or less
  • Willing to eat 1 or 2 portions (140 grams or 280 grams) of either tuna or sardines per week for a period of 8 weeks
  • Not consuming fish oil supplements
  • Not consuming protein supplements
  • Not allergic to seafood

Exclusion Criteria:

  • Regularly eat fish or not willing to do washout period where they reduce fish consumption
  • Are allergic to seafood
  • Are taking fish oil supplements or are taking protein supplements
  • Are pregnant or menopausal
  • Have very short hair (a small section of hair, approximately 200 strands, will be taken at the nap of the neck for analysis purposes)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group
No fish
Lunch containing no fish
Experimental: 1 portion of fish per week
140g fish/week
Lunch containing fish
Experimental: 2 portions of fish per week
280g fish/week
Lunch containing fish

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Polyunsaturated fatty acid (PUFA) status
Time Frame: Change at 8 weeks from baseline
Serum Polyunsaturated fatty acid (PUFA) status
Change at 8 weeks from baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hair mercury
Time Frame: Change at 8 & 16 weeks from baseline
Hair mercury status
Change at 8 & 16 weeks from baseline
Lipid profile
Time Frame: Change at 8 weeks from baseline
Serum lipid profile
Change at 8 weeks from baseline
Iodine
Time Frame: Change at 8 weeks from baseline
Urine iodine
Change at 8 weeks from baseline
Inflammatory status
Time Frame: Change at 8 weeks from baseline
Cytokine concentration (Interleukin (IL)-5, IL-1β, IL-2, IL-4, IL-6, IL-10, MCP-1, TARC, sFlt-1, VEgF-D, CRP, TNF-α, IFN-γ)
Change at 8 weeks from baseline
Oxidative stress
Time Frame: Change at 8 weeks from baseline
Change in glutathione peroxidase and 8-isoprostanes
Change at 8 weeks from baseline
Microbiota
Time Frame: Change at 8 weeks from baseline
Faecal microbiota profile
Change at 8 weeks from baseline
Thyroid hormones
Time Frame: Change at 8 weeks from baseline
Serum T3, T4 and thyroid-stimulating hormone (TSH). Dried blood spot for thyroglobulin, T4 and TSH
Change at 8 weeks from baseline
Stable isotopes
Time Frame: Change at 8 & 16 weeks from baseline
Hair methyl-mercury and sulphur-34
Change at 8 & 16 weeks from baseline
Methyl-mercury (MeHg)
Time Frame: Change at 8 weeks from baseline
Whole blood and urine MeHg
Change at 8 weeks from baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2016

Primary Completion (Actual)

May 31, 2017

Study Completion (Actual)

May 31, 2017

Study Registration Dates

First Submitted

December 4, 2018

First Submitted That Met QC Criteria

December 4, 2018

First Posted (Actual)

December 5, 2018

Study Record Updates

Last Update Posted (Actual)

December 5, 2018

Last Update Submitted That Met QC Criteria

December 4, 2018

Last Verified

December 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • REC/16/0077

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polyunsaturated Fatty Acid (PUFA) Status

Clinical Trials on Control

Subscribe